Olympus Reports Revenue Growth Despite Regulatory Ship Holds

The Tokyo-based medical technology firm reported that the Gastrointestinal Solutions business served as the primary engine for growth, generating 168.4 billion yen. This 21% increase helped offset a 4% decline in constant currency revenue for the Surgical and Interventional Solutions segment, which was hampered by voluntary ship holds and ongoing FDA-related import alerts. Despite these hurdles, core franchises such as Urology and Respiratory recorded double-digit growth.

Adjusted operating profit surged 133% to 30.7 billion yen, bolstered by disciplined expenditure and improved margins within the gastrointestinal sector. Chief Financial Officer Michael Parenti noted that the company’s performance aligns with earlier projections, despite the early stage of the fiscal year. Olympus remains in active discussions with the FDA regarding its quality remediation program and anticipates resuming normal shipment levels for affected products by the second half of the fiscal year. Brian Barry, who took over as Chief Quality Officer on August 1, will oversee these regulatory efforts as the company works to normalize its supply chain and scale internal efficiency gains.